Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
Clinical trial NCT03476239 · COMPLETED
Trial details
- NCT number
- NCT03476239
- Sponsor
- Amgen
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-10-18
- Primary completion
- 2019-08-21
- Enrollment
- 121
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.